CVS Health stock received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 73. Please watch the video ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

On the positive side, CVS is a more diversified healthcare company than Walgreens. CVS isn't just a leading pharmacy chain (which, like Walgreens, also sells some groceries and other items). It is ...

CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...

Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $70 from $66 and keeps a Buy rating on the shares. The company issued a ...

CVS Health's outlook for 2025 and beyond remains positive. However, a mix of industrywide and company-specific challenges are putting pressure on its operations and financial performance.

CVS Health reported fourth-quarter revenue and profit that topped ... insulin prices Pfizer says drug for deadly cancer ...

In this article, we are going to take a look at where CVS Health Corp. (NYSE ... on the back of better outlook, positive earnings performance, and news of government support.

A reescalating battle between pharmaceutical companies and pharmacy benefit managers is brewing in Washington, D.C., as President Donald Trump's new administration takes shape. The drug industry's ...